
Truly an honor to give the NIH Director’s WALS lecture today especially as the last speaker under the leadership of @NIHDirector Dr Monica Bertagnolli

Professor of Behavioral Neuroscience I Founder of @moghaddamlab | author of KETAMINE mitpress.mit.edu/97802625422…

Truly an honor to give the NIH Director’s WALS lecture today especially as the last speaker under the leadership of @NIHDirector Dr Monica Bertagnolli

Order your supplies and back generator while you wait

I was on all things considered today talking about this historic election and Texas’s forgotten history of economic populism one.npr.org/i/nx-s1-6030759:…

Dreadds work in humans nejm.org/doi/full/10.1056/NE…

Not true! You should read my book!
Texas isn’t Texas anymore

This morning my friend Karl won a Nobel Prize and I solved Wordle in three guesses. Historians will argue which is the greater achievement, but I think he's probably going to edge me out. med.stanford.edu/news/all-ne…

Recommend this review especially since we have actual data now to support (or refute!) some of the theories here on how psychedelics may influence reward learning and behavioral flexibility biorxiv.org/content/10.64898…
Serotonin biology as a basis for explaining psychedelic drug action - we learned a lot writing this review for @CurrentBiology cell.com/current-biology/ful… We know a good deal about serotonin, which should teach us how psychedelics work. But what’s the same? What’s different? 🤔 1/4

Amazing recognition for this remarkable discovery that has fueled modern neuroscience. Congratulations to all!!
BREAKING NEWS The 2026 #NobelPrize in Physiology or Medicine has been awarded to Karl Deisseroth, Peter Hegemann and Georg Nagel “for their discoveries concerning light-gated ion channels and optogenetics.”

Developmental changes in GRIN2A expression may help explain the timing of psychosis in #Schizophrenia and support stage-specific and genetically informed treatment approaches. ja.ma/4ying06

And I was not just theorizing: the ideas are supported by several recent preclinical papers including this from the lab nature.com/articles/s41380-0…

Please check out my futuristic opinion piece in @JAMAPsych "specific treatments for schizophrenia that are tailored to target symptoms at different developmental stages are no longer the stuff of science fiction, but instead are realistic future goals" jamanetwork.com/journals/jam…

Outstanding choice Orexin FTW!! Long, long , long overdue.
🏆 Congratulations to this year’s #LaskerAward winners! Basic: Emmanuel Mignot & Masashi Yanagisawa Clinical: Kunihiro Hattori, Tomoyuki Igawa & Takehisa Kitazawa Public Service: Michael J. Fox Laskerfoundation.org #Lasker2026 #LaskerLaureate


Excited to share our new paper in Psychopharmacology: A pilot study comparing high-dose oral Δ9-THC, psilocybin, and placebo under the same set and setting used in psychedelic clinical trials. @JHPsychedelics 🧵 link.springer.com/article/10… 1/14


It is indeed important to consider the 60's &70's papers that showed adverse effects of unsupervised LSD use (e.g. sciencedirect.com/science/ar… ) However, if there was adequate clinical supervision, the incidence of such reactions were super low (e.g. Malleson, Br J Psychiat 118:229)
Psychedelics have sordid history in psychiatry. By mid 1960’s, LSD, psilocybin production for ”therapeutic purposes” was halted because of adverse events. Only when intense sessions pre-, during, post-drug dosing were used and most volunteers excluded, did safety margin improve.